参考文献/References:
[1]Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment.Int J Hyperthermia,2017,33(5):511-519.
[2]Chicago Consensus Working Group. The Chicago consensus on peritoneal surface malignancies: management of appendiceal neoplasms. Cancer,2020,126(11):2525-2533.
[3]PatrickBrown T, Carr NJ, Swanson DM, et al. Estimating the prevalence of pseudomyxoma peritonei in Europe using a novel statistical method.Ann Surg Oncol,2020,28(1):252-257.
[4]Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei.Surg Oncol Clin N Am,2003,12(3):585-603.
[5]Elias D, Duchalais E, Dartigues P, et al. A new policy regarding ovarian resection in young women treated for peritoneal carcinomatosis. Ann Surg Oncol,2013,20(6):1837-1842.
[6]Bignell MB, Mehta AM, Alves S, et al. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.Colorectal Dis,2018,20(8):704-710.
[7]Pietrantonio F, Perrone F, Mennitto A, et al. Toward the molecular dissection of peritoneal pseudomyxoma. Ann Oncol,2016,27(11):2097-2103.
[8]Pietrantonio F, Berenato R, Maggi C, et al. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic apecitabine and bevacizumab: a clinical and translational study.Transl Med,2016,14(1):125.
[9]Gleeson EM, Feldman R, Mapow BL, et al. Appendixderived pseudomyxoma peritonei (PMP): molecular profiling toward treatment of a rare malignancy.Am J Clin Oncol,2018,41(8):777-783.
[10]Saarinen L, Nummela P, Thiel A, et al. Multiple components of PKA and TGFβ pathways are mutated in pseudomyxoma peritonei. PLoS One,2017,12(4):e0174898.
[11]Yan F, Lin Y, Zhou Q, et al. Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases. Humam Pathol,2020,97:9-18.
[12]李方,齐长海,卢一艳,等.高级别阑尾黏液性肿瘤伴腹膜假黏液瘤 9 例临床病理分析.诊断病理学杂志,2017,4(6):406-410.
[13]Horn LC, Einenkel J, Handzel R, et al. Morphology of secondary ovarian tumors and metastases. Pathologe,2014,35(4):336-347.
[14]马旭兰,付凤仙.黏液性卵巢癌的诊治进展.中国微创外科杂志,2020,20(11):1040-1045.
[15]Narasimhan V, Wilson K, Britto M, et al. Outcomes following cytoreduction and hipec for pseudomyxoma peritonei: 10-year experience. J Gastrointest Surg,2020,24(4):899-906.
[16]李庆水,付凤仙,张师前,等.黏液性卵巢癌诊断与治疗中国专家共识(2021年版).中国微创外科杂志,2021,21(7):577-588.
[17]Cheng A, Li M, Kanis MJ, et al. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and metaanalysis. Gynecol Oncol,2017,144(1):215-222.
[18]Zhang W, Tan C, Xu MD, et al. Primary appendiceal mucinous neoplasm:Gynecological manifestations,management, and prognosis. Gynecol Oncol,2020,156(2):357-362.
[19]Govaerts K, Lurvink RJ, De Hingh IHJT．Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. ESJO,2021,47(1):11-35.
[20]Elias D, Duchalais E, David A, et al. Comprehensive study of ovarian etastases in young women with peritoneal pseudomyxoma: Is a preservation of fertility possible? EJSO,2013,39(7):748-753.
[21]Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors.Gynecol Oncol,2004,93(1):87-91.
[22]Papageorgiou D, Manatakis DK, Papakonstantinou K, et al. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Arch Gynecol Obstetr,2020,302(4):793-799．
[23]Elias D，Gilly F，Quenet F，et al. Pseudomyxoma peritonei：a French muhicentric study of 301 patients treated with eytoreduetive surgery and intraperitoneal chemotherapy.Eur J Surg Oncol,2010,36(5):456-462．
[24]Chua TC, Liauw W, Zhao J, et al. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and eoloreetal peritoneal eareinomatosis. Int J Clin Oncol,2013,18(3):439-446．
[25]Ahmadi N, Kostadinov D, Sakata S, et al. Managing recurrent pseudomyxoma peritonei in 430 patients after complete cytoreduction and HIPEC: A dilemma for patients and surgeons.Ann Surg Oncol, 2021,28(12):7809-7820.
[26]Sugarbaker PH. Are there curative options to peritoneal carcinomatosis? Ann Surg,2005,242(5):748-750．
[27]OrtegaDeballon P, Glehen O, Levine E, et al. Childbearing after hyperthermic intraperitoneal chemotherapy: Results from an international survey.Ann Surg Oncol,2011,18(8):2297-2301.
[28]Kyser K, Bidus MA, Rodriguez M, et al. Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal hemotherapy. Gynecol Oncol,2006,100(1):198-200.
[29]Sheehan LA, Mehta AM, Sawan S, et al. Preserving fertility in pseudomyxoma peritonei, a novel approach.Pleura Peritoneum,2017,2(1):33-36.
[30]Chen H, Xiao L, Li J, et al. Adjuvant gonadotropinreleasing hormone analogues for the prevention of chemotherapyinduced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev,2019,2(1):33-36.
[31]Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens-the role of gonadotropinreleasing hormone agonists.Expert Opin Pharmacother,2016,16(7):1009-1020.
[32]Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection.Hum Reprod Update,2019,25(6):673-693.
[33]Cianos R, Lafever S, Mills N. Heated intraperitoneal chemotherapy in appendiceal cancer treatment. Clin J Oncol Nurs,2013,17(1):84-87.
[34]Campanati RG, Hanan B, de Souza SS, et al. Pregnancy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei.Surgery,2014,6(11):1-3.
[35]GómezPortilla A, Olabarria I, Martín E, et al. Natural conception after fertilityconserving cytoreductive surgery (FCCRS) and heated intraperitoneal hemotherapy (HIPEC) with the oxaliplatin protocol: a case report.Int J Surg Res,2015,4(1):4-6.
[36]de Assis V, Saunders R,Adams J,et al. In vitro fertilization pregnancy following treatment of diffuse malignant peritoneal mesothelioma.J Case Rep Images Obstet Gynecol,2019,5(8):1.
[37]Tan GHC, Chia CS, Tan SH, et al. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC).Int J Clin Oncol,2018,23(5):989-998.
[38]Mercier F, Dagbert F, Pocard M, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open,2019,3(2):195-202.
[39]Filippi F, Kusamura S, Martinelli F,et al. Fertility preservation in women with peritoneal surface malignancies: A case series. EJSO,2021,47(11):2948-2951.
[40]Hartnett KP, Mertens AC, Kramer MR, et al. Pregnancy after cancer: does timing of conception affect infant health? Cancer,2018,124(22):4401-4407.